Roger Crystal brings more than 15 years of experience as a healthcare business executive and clinician. He is a pioneer in the development of intranasal naloxone treatments for opioid overdose. He led Opiant’s development of nasal naloxone for opioid overdose, which led to FDA approval, and is the lead inventor on the product’s patents. He is an expert in addiction, recently testifying at The White House.
He was CBO for ImaginAb, a Los Angeles based VC backed biotech, and was responsible for acquisitions, licensing and partnering deals at GE Healthcare. He began his business career as a management consultant at A.T. Kearney. Prior this he worked as a surgeon in the UK at leading institutions including Imperial College London. He was awarded the MRCS from the Royal College of Surgeons, was an Honorary Research Fellow at UCL, UK, has authored several peer-reviewed scientific articles. He holds a BMedSci and MD from the University of Birmingham and an MBA from London Business School